Stony Brook Medicine is tapping its research base to help find ways to ease the symptoms and effects of COVID-19 on inpatients.
“In addition to providing outstanding care to our patients, it is our responsibility to better understand the disease and identify novel ways to prevent or treat our patients, as a research-intense academic medical school and academic hospital,” said Dr. Kenneth Kaushansky, Sr. Vice President for Health Sciences and Dean of the Renaissance School of Medicine.
“The challenge is being met with an impressive level of intensity and rigor,” Dr. Kaushansky said.
Clinical trials that doctors and researchers of Stony Brook Medicine are currently working on include:
- Efficacy and safety of sarilumab for hospitalized patients with COVID-19.
- Use of estrogen patch for treatment of COVID-19.
- A population-controlled study to compare the safety and efficacy of Hydroxychloroquine (HCQ) Sulfate and Vitamin C in healthcare workers (HCWs) at risk for COVID-19.
- Therapeutic efficacy of Losartan for hypertension in patients with COVID-19.
- Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the treatment of SARS-CoV2 (CoV).
- Infection, which focuses on individuals over the age of 18 that have been hospitalized with confirmed SARS CoV2 and who are or known contact requiring invasive mechanical ventilation.
- Remdesivir-RVD, GS5734, for the treatment of coronavirus (CoV) infection in children.
- Convalescent Plasma vs. Standard Plasma for patients admitted with COVID-19: This trial requires hospitalized patients 18 years or older that have had a positive test within 14 days of admission.
In addition to clinical trials, there are several observational trials in the works at Stony Brook University Hospital. These include:
- TemPredictSB is a COVID-19 responsive emergency research study to build personal COVID-19 early-detection and symptom monitoring systems using data from wearable devices (OuraRing.com). TemPredictSB will allow Stony Brook researchers to evaluate our own community of healthcare workers to better understand risks of COVID-19 to frontline staff.
- Convalescent Plasma vs Standard Plasma: This trial requires hospitalized patients 18 years or older that have had a positive test within 14 days of admission.
- COVID-19 patients at Stony Brook Medicine: Clinical diagnosis of COVID-19 pneumonia (either positive test or “person under investigation” status).
- Remdesivir-RVD, GS5734, for the treatment of Selected Coronavirus (CoV) Infection, Single Patient Protocol for pediatrics.
- COVID-19 AI: Utilizing Artificial Intelligence (AI) algorithms on CT and X-ray images to classify COVID-19 positive subjects from normal or other lung infections.
- A North American Registry of the Digestive Manifestations of COVID-19: Confirmed Dx of COVID-19 treated at Stony Brook University Hospital.
Run by several of the top medical professionals at Stony Brook Medicine, including Dr. Sharon Nachman, Chief of the Division of Pediatric Infectious Diseases at Stony Brook Children’s Hospital and Associate Dean for Research, Renaissance School of Medicine at Stony Brook University; Dr. Bettina Fries, Chief of the Division of Infectious Diseases in the Department of Medicine at the Renaissance School of Medicine at Stony Brook University; and Dr. Adam Singer, Professor and Vice Chair for Research, Department of Emergency Medicine, these trials have been developed to observe the impact of different types of treatment on coronavirus patients, as well as help further advance possible remedies.